Study backs T-wave alternans test:
This article was originally published in Clinica
Executive Summary
Measuring T-wave alternans, subtle beat-to-beat fluctuations in heartbeat, could help predict ventricular tachycardia (VT) in patients with non-ischaemic dilated cardiomyopathy (DCM), according to a study published in the Journal of the American College of Cardiology (August). The sensitivity, specificity and predictive accuracy of T-wave alternans for VT in 58 patients with DCM were 88%, 72% and 77% respectively. US company Cambridge Heart of Bedford, Massachusetts, which makes the only non-invasive T-wave alternans test with FDA clearance, said the findings were significant since a conventional electrophysiology study is not considered useful in diagnosing patients with non-ischaemic DCM.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.